Copyright
©2014 Baishideng Publishing Group Co.
World J Hematol. May 6, 2014; 3(2): 18-28
Published online May 6, 2014. doi: 10.5315/wjh.v3.i2.18
Published online May 6, 2014. doi: 10.5315/wjh.v3.i2.18
Advantages | Disadvantages | |
Bone marrow | 1 The longest history as a source of HSC | 1 High stringency for HLA matching |
2 Well established procedure | 2 Some complications associated with harvesting | |
3 Risk of GVHD | ||
Umbilical cord blood | 1 Off-the-shelf availability | 1 Delayed engraftment |
2 Reduced stringency for HLA matching | 2 Lower yield | |
3 Low risk of infection/transmission | 3 Lack of additional immune cells | |
4 Absence of donor risk | ||
Peripheral blood | Compared to BM, | 1 Extremely low level of HSC (1/100000) without “mobilization” |
1 More comfortable for donors | 2 Risk of GVHD | |
2 Better yield with mobilization |
Mouse | Human |
CD34low/- | CD34low/- |
Sca-1+ | Sca-1+ |
CD90/Thy-1+/low | CD90/Thy-1+/low |
c-Kit+ | c-Kit+ |
CD38+ | CD38- |
CD150+ | CD7- |
Side population (high hoechst-efflux activity) | CD49f+ |
CD48- | Rhodamine 123low |
CD244- | CD133/AC133- |
Lin- | CD45RA- |
Lin- |
-
Citation: Kita K, Xiu F, Jeschke MG.
Ex vivo expansion of hematopoietic stem and progenitor cells: Recent advances. World J Hematol 2014; 3(2): 18-28 - URL: https://www.wjgnet.com/2218-6204/full/v3/i2/18.htm
- DOI: https://dx.doi.org/10.5315/wjh.v3.i2.18